Drug Trial Radar · NCT05330884
BCG Revaccination in Children and Adolescents
Last checked: Nov 19, 2026Latest source record: Dec 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
9,200
Planned (sponsor's estimate)
Start
Jul 15, 2024
Primary completion
Jun 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Tuberculosis Research Centre, IndiaGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Institute of Child Health, Chennai; All India Institute of Medical Sciences; The Grant Medical College & Sir J.J. Group of Hospitals; All India Institute of Medical Sciences, Bhubaneswar; Rajendra Institute of Medical Sciences, Ranchi; National Institute of Tuberculosis and Respiratory Diseases, New Delhi; Rajiv Gandhi Hospital, Chennai; Madurai Medical College; Government Vellore Medical College, Vellore
- First posted
- Apr 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Bacille Calmette Guerin (BCG) vaccine is one of the most used vaccines of the world, to reduce the risks of natural tuberculous infection. The efficacy of BCG vaccination in newborns is well known and has a documented protective effect against meningitis and disseminated TB in children. However, there is considerable uncertainty on BCG revaccination. It is known that BCG revaccination enhances immune responses, but it is yet to be established if BCG revaccination can help prevent TB disease in household contacts. The primary aim of this study is to assess the efficacy of BCG revaccination compared to oral chemoprophylaxis in preventing TB disease in house hold contacts aged 6-18 years. The study is designed as a multicentre randomised controlled trial with two groups of healthy household contacts aged 6-18 years receiving either the BCG vaccine or oral chemoprophylaxis. They will be followed up for 24 months to compare the incidence of TB disease in each arm.
Conditions
- Tuberculosis Infection
- Tuberculosis
Interventions
BCG vaccineBiological
0.1ml BCg vaccine to be given intradermally
Oral ChemoprophylaxisDrug
Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TB (all forms - PTB / EPTB) as per NTEP guidelinesTime frame: over 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dr Aishwarya Venkataraman
Chennai, Tamil Nadu, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.